Balyasny Asset Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Balyasny Asset Management’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-913,940	Closed	-$42.5M	–	2879
2023 Q2	$42.5M	Buy	+913,940	New	+$31.6M	0.09%	297
2023 Q1	–	Sell	-398,477	Closed	-$12.4M	–	3327
2022 Q4	$12.4M	Sell	398,477 -61,200	-13%	-$2M	0.03%	649
2022 Q3	$9.32M	Buy	459,677 +184,856	+67%	+$3.37M	0.03%	721
2022 Q2	$4.26M	Buy	+274,821	New	+$4.73M	0.01%	1010

Balyasny Asset Management's DICE Position: Q3 2023 in Review

Balyasny Asset Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 913,940 shares — an estimated $42.5M sold.

Balyasny Asset Management first reported a position in DICE in Q2 2022 and held it in 4 quarters. The position peaked at $42.5M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Balyasny Asset Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Balyasny Asset Management sold 913,940 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $42.5M.
Balyasny Asset Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Balyasny Asset Management's DICE Therapeutics, Inc. Common Stock position peaked at $42.5M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.